<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bloodjour</journal-id><journal-title-group><journal-title xml:lang="ru">Гематология и трансфузиология</journal-title><trans-title-group xml:lang="en"><trans-title>Russian journal of hematology and transfusiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0234-5730</issn><issn pub-type="epub">2411-3042</issn><publisher><publisher-name>ООО Издательский дом «Практика»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35754/0234-5730-2025-70-3-311-319</article-id><article-id custom-type="elpub" pub-id-type="custom">bloodjour-661</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Факторы риска рецидива цитомегаловирусного ретинита у детей — реципиентов аллогенных гемопоэтических стволовых клеток</article-title><trans-title-group xml:lang="en"><trans-title>Risk factors for recurrence of cytomegalovirus retinitis in children receiving allogeneic hematopoietic stem cell transplantation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6481-8608</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Першин</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Pershin</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Першин Борис Сергеевич, кандидат медицинских наук, офтальмолог</p><p>117198, г. Москва</p></bio><bio xml:lang="en"><p>Boris S. Pershin, Cand. Sci. (Med.), ophthalmologist</p><p>117198, Moscow</p></bio><email xlink:type="simple">bpershin1984@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0016-6698</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Масчан</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maschan</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Масчан Алексей Александрович, доктор медицинских наук, профессор, член-корр. РАН, заместитель генерального директора по научно-клинической работе</p><p>117198, г. Москва</p></bio><bio xml:lang="en"><p>Alexei A. Maschan, Dr. Sci. (Med.), Professor, corresponding member of the RAS, Deputy Director</p><p>117198, Moscow</p></bio><email xlink:type="simple">Aleksey.Maschan@fccho-moscow.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3585-7595</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Анна Борисовна, офтальмолог</p><p>117198, г. Москва</p></bio><bio xml:lang="en"><p>Anna B. Smirnova, ophthalmologist</p><p>117198, Moscow</p></bio><email xlink:type="simple">anja03@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2025</year></pub-date><volume>70</volume><issue>3</issue><fpage>311</fpage><lpage>319</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Першин Б.С., Масчан А.А., Смирнова А.Б., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Першин Б.С., Масчан А.А., Смирнова А.Б.</copyright-holder><copyright-holder xml:lang="en">Pershin B.S., Maschan A.A., Smirnova A.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.htjournal.ru/jour/article/view/661">https://www.htjournal.ru/jour/article/view/661</self-uri><abstract><sec><title>Введение</title><p>Введение. Цитомегаловирусный ретинит (ЦМВР) — это некротическое заболевание сетчатки, которое может стать причиной необратимой слепоты. Увеличение количества эпизодов ЦМВР увеличивает вероятность развития необратимой слепоты. Снижение риска развития рецидива ЦМВР позволит повысить эффективность зрительной реабилитации данной категории больных.</p></sec><sec><title>Цель</title><p>Цель: изучить закономерности и факторы риска развития рецидива ЦМВР у детей — реципиентов гемопоэтических стволовых клеток.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 37 больных в возрасте от 0 до 21 года (62 глаза), перенесших ЦМВР и трансплантацию гемопоэтических стволовых клеток, получивших серию интравитреальных введений (ИВВ) противовирусных препаратов. Рецидивы ЦМВР произошли у 7 больных. У 3 больных рецидив был на 1 глазу, у 4 — на обоих. Из 62 глаз без рецидивов было 51, с одним рецидивом — 6 и более чем с одним рецидивом — 5. В 23 из 81 эпизода был диагностирован рецидив. Достижение ремиссии диагностировали при установлении отсутствия ДНК цитомегаловируса в образце водянистой влаги, которую забирали из передней камеры глаза или/и полного заживления очагов ЦМВР при помощи офтальмоскопии.</p></sec><sec><title>Результаты</title><p>Результаты. Прекращение ИВВ противовирусных препаратов на основании негативизации результатов полимеразной цепной реакции внутриглазной жидкости уменьшает вероятность рецидива более чем в 16 раз по сравнению с принятием решения на основании офтальмоскопических данных (p = 0,011) и более чем в 2 раза по сравнению с «ненулевыми» результатами ПЦР.</p></sec><sec><title>Заключение</title><p>Заключение. Рецидивирующий характер течения ЦМВР связан с репликацией копий вируса внутри глаза. Элиминация копий вируса из внутриглазной жидкости уменьшает вероятность развития рецидива ЦМВР</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Cytomegalovirus retinitis (CMVR) is a necrotizing disease of the retina that can cause irreversible blindness. An increase in the number of CMVR episodes increases the likelihood of developing irreversible blindness. Reducing the risk of CMVR recurrence will improve the effectiveness of visual rehabilitation for this category of patients. Aim: To study the patterns and risk factors for the development of CMVR recurrence in children who are recipients of hematopoietic stem cells.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 37 patients aged 0 to 21 years (62 eyes) who had undergone CMVR and hematopoietic stem cell transplantation and received a series of intravitreal injections (IVI) of antiviral drugs. CMVR recurrences occurred in seven patients. In 3 patients, there was a recurrence in 1 eye, in 4 — in both eyes. Of the 62 eyes, 51 had no recurrences, 6 had one recurrence, and 5 had more than one recurrence. A recurrence was diagnosed in 23 out of 81 episodes. Remission was considered achieved when the absence of cytomegalovirus DNA was confi rmed in a sample of aqueous humor taken from the anterior chamber of the eye and/or upon complete healing of CMVR lesions as determined by ophthalmoscopy.</p></sec><sec><title>Results</title><p>Results. Discontinuation of IV antiviral drugs based on negative aqueous humor PCR results reduces the likelihood of recurrence by more than 16 times compared to a decision based on ophthalmoscopic data (p-value = 0.011) and by more than 2 times compared with non-zero PCR results.</p></sec><sec><title>Conclusion</title><p>Conclusion. The recurrent nature of the course of CMVR is associated with the replication of virus copies inside the eye. Elimination of copies of the virus from the intraocular fl uid reduces the likelihood of developing a CMVR recurrence.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цитомегаловирусный ретинит</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytomegalovirus retinitis</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Keijer W.J., Burger D.M., Neuteboom G.H., et al. Ocular complications of the acquired immunodefi ciency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharm World Sci. 1993;15(2):56–67. DOI: 10.1007/BF01874084.</mixed-citation><mixed-citation xml:lang="en">Keijer W.J., Burger D.M., Neuteboom G.H., et al. Ocular complications of the acquired immunodefi ciency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet. Pharm World Sci. 1993;15(2):56–67. DOI: 10.1007/BF01874084.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Iu L.P., Fan M.C., Lau J.K., et al. Long-term follow-up of cytomegalovirus retinitis in non-HIV immunocompromised patients: Clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53. DOI: 10.1016/j.ajo.2016.03.015.</mixed-citation><mixed-citation xml:lang="en">Iu L.P., Fan M.C., Lau J.K., et al. Long-term follow-up of cytomegalovirus retinitis in non-HIV immunocompromised patients: Clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53. DOI: 10.1016/j.ajo.2016.03.015.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon S., Lee W.K., Lee Y., et al. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell trans-plantation. Ophthalmology. 2012;119(9):1892–8. DOI: 10.1016/j.ophtha.2012.03.032.</mixed-citation><mixed-citation xml:lang="en">Jeon S., Lee W.K., Lee Y., et al. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell trans-plantation. Ophthalmology. 2012;119(9):1892–8. DOI: 10.1016/j.ophtha.2012.03.032.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kotton C.N., Kumar D., Caliendo A.M., et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60. DOI: 10.1097/TP.0b013e31829df29d.</mixed-citation><mixed-citation xml:lang="en">Kotton C.N., Kumar D., Caliendo A.M., et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60. DOI: 10.1097/TP.0b013e31829df29d.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ariza-Heredia E.J., Nesher L., Chemaly R.F. Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review. Cancer Lett. 2014;342(1):1– 8. DOI: 10.1016/j.canlet.2013.09.004.</mixed-citation><mixed-citation xml:lang="en">Ariza-Heredia E.J., Nesher L., Chemaly R.F. Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review. Cancer Lett. 2014;342(1):1– 8. DOI: 10.1016/j.canlet.2013.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mizushima D., Nishijima T., Gatanaga H., et al. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era. PLoS One. 2013;8(5):e65348. DOI: 10.1371/journal.pone.0065348.</mixed-citation><mixed-citation xml:lang="en">Mizushima D., Nishijima T., Gatanaga H., et al. Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 infection in the HAART era. PLoS One. 2013;8(5):e65348. DOI: 10.1371/journal.pone.0065348.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Voigt S., Michel D., Kershaw O., et al. Fatal reactivation of postnatal cytomegalovirus infection with rapid emergence of ganciclovir resistance in an infant after allogeneic stem cell transplantation. J Clin Microbiol. 2005;43(7):3551–4. DOI: 10.1128/JCM.43.7.3551-3554.2005.</mixed-citation><mixed-citation xml:lang="en">Voigt S., Michel D., Kershaw O., et al. Fatal reactivation of postnatal cytomegalovirus infection with rapid emergence of ganciclovir resistance in an infant after allogeneic stem cell transplantation. J Clin Microbiol. 2005;43(7):3551–4. DOI: 10.1128/JCM.43.7.3551-3554.2005.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jabs D.A., Van Natta M.L., Kempen J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133(1):48–61. DOI: 10.1016/s0002-9394(01)01322-8.</mixed-citation><mixed-citation xml:lang="en">Jabs D.A., Van Natta M.L., Kempen J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133(1):48–61. DOI: 10.1016/s0002-9394(01)01322-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobson M.A., O’Donnell J.J., Brodie H.R., et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol. 1988;25(3):339–49. DOI: 10.1002/jmv.1890250311.</mixed-citation><mixed-citation xml:lang="en">Jacobson M.A., O’Donnell J.J., Brodie H.R., et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol. 1988;25(3):339–49. DOI: 10.1002/jmv.1890250311.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Crumpacker C.S. Ganciclovir. N Engl J Med. 1996;335(10):721–9. DOI: 10.1056/NEJM199609053351007.</mixed-citation><mixed-citation xml:lang="en">Crumpacker C.S. Ganciclovir. N Engl J Med. 1996;335(10):721–9. DOI: 10.1056/NEJM199609053351007.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Drew W.L., Ives D., Lalezari J.P., et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333(10):615–20. DOI: 10.1056/NEJM199509073331002.</mixed-citation><mixed-citation xml:lang="en">Drew W.L., Ives D., Lalezari J.P., et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995;333(10):615–20. DOI: 10.1056/NEJM199509073331002.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Teoh S.C., Ou X., Lim T.H. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: Effi cacy of a low-volume, intermediate-dose regimen. Ophthalmology. 2012;119(3):588–95. DOI: 10.1016/j.ophtha.2011.09.004.</mixed-citation><mixed-citation xml:lang="en">Teoh S.C., Ou X., Lim T.H. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: Effi cacy of a low-volume, intermediate-dose regimen. Ophthalmology. 2012;119(3):588–95. DOI: 10.1016/j.ophtha.2011.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S.R., Dogra M., Kaur S., et al. Spectrum of newly diagnosed cytomegalovirus retinitis in a developing country in the HAART era. Ocul Immunol Infl amm. 2020;28(1):119–25. DOI: 10.1080/09273948.2018.1538460.</mixed-citation><mixed-citation xml:lang="en">Singh S.R., Dogra M., Kaur S., et al. Spectrum of newly diagnosed cytomegalovirus retinitis in a developing country in the HAART era. Ocul Immunol Infl amm. 2020;28(1):119–25. DOI: 10.1080/09273948.2018.1538460.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Crippa F., Corey L., Chuang E.L., et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32(2):214–9. DOI: 10.1086/318447.</mixed-citation><mixed-citation xml:lang="en">Crippa F., Corey L., Chuang E.L., et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32(2):214–9. DOI: 10.1086/318447.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
